Physician profile
Knar Mesrobian
NPI 1124412317
$6,129.54
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $930 · 2021: $1,589 · 2022: $1,269 · 2023: $1,185 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,117.81 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $758.13 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $577.21 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $530.18 | 2019-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.71 | 2019-2023 | Jardiance |
| Amgen INC. | $370.95 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $351.83 | 2021-2023 | |
| Esperion Therapeutics, INC. | $264.20 | 2020-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $256.65 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $134.69 | 2020-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $130.17 | 2022 | |
| Glaxosmithkline, LLC. | $123.46 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Teva Pharmaceuticals USA, INC. | $109.93 | 2019-2023 | Austedo |
| Abbott Laboratories | $107.58 | 2021-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $100.25 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $84.30 | 2022-2023 | Quviviq |
| Eisai INC. | $81.65 | 2020-2022 | |
| Amarin Pharma, INC. | $75.99 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $68.07 | 2019-2023 | |
| Sanofi Pasteur INC. | $60.99 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $46.22 | 2019-2020 | |
| Exact Sciences Corporation | $44.41 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $40.38 | 2020-2021 | |
| Allergan, INC. | $40.21 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.69 | 2022-2023 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $30.99 | 2020 | |
| Boston Scientific Corporation | $17.69 | 2021 | |
| Astellas Pharma US INC | $17.54 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.57 | 2021 | |
| Neurocrine Biosciences, INC. | $15.49 | 2023 | Ingrezza |
| Hikma Pharmaceuticals USA | $14.56 | 2020 | |
| Nevro Corp. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Knar Mesrobian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.